You just read:

AbbVie Expands Immunology Portfolio in the U.S. with FDA Approval of SKYRIZI™ (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis

News provided by

AbbVie

Apr 23, 2019, 18:19 ET